Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499835 | 0.76 | EGFR (0.65) | HDAC6CCNA2CDK2CCNA1MEN1 | |
| SCHEMBL1378618 | 0.76 | KMT2A (0.56) | HDAC6CCNA2CDK2CCNA1MEN1 | |
| SCHEMBL5694143 | 0.75 | MEN1 (0.51) | HDAC6CCNA2CDK2CCNA1MEN1 | |
| SCHEMBL4589056 | 0.74 | HDAC6 (0.65) | HDAC6MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15754799 | 0.74 | HDAC6 (1.00) | HDAC6MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29396652 | 0.74 | HDAC6 (1.00) | HDAC6MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7669653 | 0.72 | RAB9A (0.64) | HDAC6CCNA2CDK2CCNA1MEN1 | |
| SCHEMBL29220747 | 0.72 | HCAR3 (0.71) | HDAC6MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28102830 | 0.72 | IP6K1 (0.60) | MEN1KMT2ANPC1RAB9ABRD4 | |
| SCHEMBL210467 | 0.71 | KMT2A (0.64) | HDAC6CCNA2CDK2CCNA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | HDAC6 263/4885CCNA2 2788/4885CDK2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.